BREAKING NEWS - BMS close to selling its stake in diabetes alliance to AZ

[Anonymous]

According to people familiar with the matter, Bristol-Myers Squibb is close to a deal worth more than $3 billion to divest its stake in a diabetes partnership with AstraZeneca, The Wall Street Journal reported Wednesday. In November, Bristol-Myers Squibb revealed that it was halting drug discovery in diabetes, leading to speculation that the drugmaker planned to exit the venture. According to the sources, an agreement could be reached as early as December 18.

 

[Anonymous]

So, there must have been some financial triggers tied it dapa approval for this to become public in 3 business days...

 

[Anonymous]

Has to be Non-us! 3 billion is way to low..

 

[Anonymous]

Has to be Non-us! 3 billion is way to low..

Astra is desperate

 

[Anonymous]

And BMS sales force is in trouble!

 

[Anonymous]

It's non-US. Nothing is changing here. Alliance is strong

 

[Anonymous]

Yes this is non-US deal!!

 

[Anonymous]

It's non-US. Nothing is changing here. Alliance is strong

Keep drinking your BMS Kool-aid. Most likely it is the US. I guess we will have to wait to see how they spin it.

 

[Anonymous]

Well it makes sense to be non US! We paid 3.5 billion for just Amylin's products.

 

[Anonymous]

Well it makes sense to be non US! We paid 3.5 billion for just Amylin's products.

After which AZ immediately paid BMS $3.4 billion to create the JV. Which isn't worth nearly what it was at that time.

 

[Anonymous]

Yes this is non-US deal!!

Doubt it!! BMS will cut it's losses and get a tax break. Doesn't make sense for them to keep US JV Alliance and drop non US market. It's all or nothing. BMS needs the money to focus on what's more profitable and it's not the "me too" diabetes drugs. Inside sources say it's the entire JV.

Time will tell.

 

[Anonymous]

Doubt it!! BMS will cut it's losses and get a tax break. Doesn't make sense for them to keep US JV Alliance and drop non US market. It's all or nothing. BMS needs the money to focus on what's more profitable and it's not the "me too" diabetes drugs. Inside sources say it's the entire JV.

Time will tell.

My inside source said it was non US! Yup guess we will see.

 

[Anonymous]

Things won't change much until about 3rd quarter.

 

[Anonymous]

Doubt it!! BMS will cut it's losses and get a tax break. Doesn't make sense for them to keep US JV Alliance and drop non US market. It's all or nothing. BMS needs the money to focus on what's more profitable and it's not the "me too" diabetes drugs. Inside sources say it's the entire JV.

Time will tell.

3 billion seems so low! Analysis said 4 to 6 billion for non US market.

 

[Anonymous]

Amylin acquisition cost BMS over $5bil alone.

 

[Anonymous]

Merry fucking x-mas!! Seriously they couldn't have waited until January 2nd to tell
Us.

 

[Anonymous]

Has to be Non-us! 3 billion is way to low..

Amylin purchase was $7b, of which $1.7b went to pay-off Eli Lilly.
AZ paid $3.4b
BMS selling out for $3b, a clean break.

 

[Anonymous]

He's right above. Well said.

 

[Anonymous]

Sort of interesting that late on Tuesday we got notice of a GLOBAL EMPLOYEE MEETING w/ Lamberto to be held at 9:30 am on Thursday. I figure we'll have a major announcement in our inbox first thing in the morning...

 

[Anonymous]

Merry fucking x-mas!! Seriously they couldn't have waited until January 2nd to tell
Us.

As if you didn't know already